Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category 1 drug candidate, UBT251, has been tacitly approved in China for a clinical study to assess its effectiveness against overweight and obesity conditions.
UBT251: A Triple Agonist for Metabolic Conditions
UBT251 is a long-acting GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulin-stimulating peptide)/GCG (glucagon) triple agonist prepared by chemical synthesis of peptides. This drug candidate has shown potential in treating various metabolic conditions. Last month, UBT251 earned clinical approval for the treatment of type 2 diabetes, and a clinical filing for the treatment of non-alcoholic fatty liver disease/nonalcoholic steatohepatitis is currently under final review.
Competition with Eli Lilly’s Retatrutide
UBT251 joins the ranks of other triple agonists in development, with Retatrutide, Eli Lilly’s world-leading GLP-1/GCG/GIP triple agonist, having entered Phase III clinical trials. The tacit approval of UBT251 in China signifies the growing interest and investment in innovative treatments for obesity and related metabolic disorders.-Fineline Info & Tech
